計畫
(Principal Investigator)


第 1 到 25 筆結果，共 25 筆。

啟始時間標題P-Investigator經費來源
2023Establishing Immuno-Competent Mouse Esophageal Squamous Cell Carcinoma Models for Developing Strategies to Improve the Efficacy of Anti-Pd-1/Pd-L1 Immune Checkpoint Blockade( II )CHIH-HUNG HSUNational Science and Technology Council
2022Establishing Immuno-Competent Mouse Esophageal Squamous Cell Carcinoma Models for Developing Strategies to Improve the Efficacy of Anti-Pd-1/Pd-L1 Immune Checkpoint Blockade( I )CHIH-HUNG HSUNational Science and Technology Council
2021Targeting Myeloid-derived Suppressor Cells (MDSCs) to Improve the Therapeutic Efficacy of Programmed Cell Death Protein-1 (PD-1)-blockade Immunotherapy against CancersCHIH-HUNG HSUNational Science and Technology Council
2020Targeting Myeloid-derived Suppressor Cells (MDSCs) to Improve the Therapeutic Efficacy of Programmed Cell Death Protein-1 (PD-1)-blockade Immunotherapy against CancersCHIH-HUNG HSUNational Science and Technology Council
2019Targeting Myeloid-Derived Suppressor Cells (Mdscs) to Improve the Therapeutic Efficacy of Programmed Cell Death Protein-1 (Pd-1)- Blockade Immunotherapy against CancersCHIH-HUNG HSUNational Science and Technology Council
2019Targeting Myeloid-derived Suppressor Cells (MDSCs) to Improve the Therapeutic Efficacy of Programmed Cell Death Protein-1 (PD-1)-blockade Immunotherapy against CancersCHIH-HUNG HSUNational Science and Technology Council
2018Deciphering Tumor Immune-Microenvironment in Predciting the Efficacy of Program Cell Death 1 (Pd-1) Checkpoint Bloackade Therapy in Esophageal Squamous Cell CarcinomaCHIH-HUNG HSUNational Science and Technology Council
2017Deciphering Tumor Immune-Microenvironment in Predciting the Efficacy of Program Cell Death 1 (Pd-1) Checkpoint Bloackade Therapy in Esophageal Squamous Cell CarcinomaCHIH-HUNG HSUNational Science and Technology Council
2016Deciphering Tumor Immune-Microenvironment in Predciting the Efficacy of Program Cell Death 1 (Pd-1) Checkpoint Bloackade Therapy in Esophageal Squamous Cell CarcinomaCHIH-HUNG HSUNational Science and Technology Council
2015Impact of Chemotherapy on Immune Microenvironment of Esophageal Squamous Cell Carcinoma---Focusing on the Immune Checkpoint RegulationCHIH-HUNG HSUNational Science and Technology Council
2014Targeting Actionable Genetic Alterations as Novel Therapeutics for Esophageal Squamous Cell CarcinomaCHIH-HUNG HSUNational Science and Technology Council
2013(100cap020-2) In vivo Resistant Mechanisms of Sorafenib in Hepatocellular Carcinoma (HCC)---Development of Predictive Biomarkers and Resistance-Reversing Strategies (III)CHIH-HUNG HSUNational Science and Technology Council
2012(100CAP020-2) In vivo Resistant Mechanisms of Sorafenib in Hepatocellular Carcinoma (HCC)---Development of Predictive Biomarkers and Resistance-Reversing Strategies (II)CHIH-HUNG HSUNational Science and Technology Council
2011(100CAP020-2) in vivo Resistant Mechanisms of Sorafenib in Hepatocellular Carcinoma (HCC)---Development of Predictive Biomarkers and Resistance-Reversing Strategies (I)CHIH-HUNG HSUNational Science and Technology Council
2010Exploring Molecular Targets for the Treatment of Hepatocellular Carcinoma---An Alternative ApproachCHIH-HUNG HSUNational Science and Technology Council
2010Factors Affecting Biomarker Detection for the Implementation of Personalized Therapy for Hepatocellular Carcinoma (HCC) and Their Optimization (II)CHIH-HUNG HSUNational Science and Technology Council
2009Exploring Molecular Targets for the Treatment of Hepatocellular Carcinoma---An Alternative ApproachCHIH-HUNG HSUNational Science and Technology Council
2009Factors Affecting Biomarker Detection for the Implementation of Personalized Therapy for Hepatocellular Carcinoma (Hcc) and Their Optimization (I)CHIH-HUNG HSUNational Science and Technology Council
2008Exploring Molecular Targets for the Treatment of Hepatocellular Carcinoma---An Alternative ApproachCHIH-HUNG HSUNational Science and Technology Council
2007PI3K/Akt/mTOR Pathway-Targeting Agents in the Treatment of Hepatocellular Carcinoma---Exploration of the Possible Clinical Applications and the Molecular MechanismsCHIH-HUNG HSUNational Science and Technology Council
2007PI3K/Akt/mTOR Pathway-Targeting Agents in the Treatment of Hepatocellular Carcinoma---Exploration of the Possible Clinical Applications and the Molecular MechanismsCHIH-HUNG HSUNational Science and Technology Council
2006PI3K/Akt/mTOR Pathway-Targeting Agents in the Treatment of Hepatocellular Carcinoma---Exploration of the Possible Clinical Applications and the Molecular MechanismsCHIH-HUNG HSUNational Science and Technology Council
2005Targeting PI3K/AKT and Related Signaling Pathways in the Treatment of Nasopharyngeal Carcinoma---Further Exploration of the Molecular Mechanisms and Clinical ImplicationsCHIH-HUNG HSUNational Science and Technology Council
2002Studies on the Mechanisms of Activation of Hepatitis B Virus (HBV) Replication Induced by Anticancer DrugsCHIH-HUNG HSUNational Science and Technology Council
2001Studies on Epstein-Barr Virus (EBV) Reactivation Induced by Anti-Cancer Drugs---Mechanisms and Clinical SignificanceCHIH-HUNG HSUNational Science and Technology Council